NCT07793318尚未招募2 期
An Open-Label, Multicenter, Phase II Exploratory Study to Evaluate the Efficacy and Safety of TR115 in Patients With ARID1A-Mutated Advanced Solid Tumors
Tarapeutics Science Inc.1 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2026年9月20日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 50
- 试验地点
- 1
- 主要终点
- Objective Response Rate (ORR)
研究概览
简要总结
This is an open-label, multicenter, exploratory Phase II study to evaluate the efficacy and safety of TR115, an EZH2 inhibitor, in patients with advanced solid tumors carrying ARID1A gene mutations. Approximately 50 participants will be enrolled into three cohorts: platinum-resistant ovarian clear cell carcinoma, endometrial cancer with prior immunotherapy failure, and other solid tumors including gastric and urothelial cancers. All participants will receive TR115 at 1200 mg orally twice daily in continuous 28-day cycles until disease progression or unacceptable toxicity. The primary endpoint is objective response rate (ORR). Secondary endpoints include duration of response, progression-free survival, overall survival, disease control rate, and safety. Exploratory biomarker analyses will also be conducted.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Able to understand and provide written informed consent.
- •Age 18 to 70 years, inclusive.
- •Histologically or cytologically confirmed advanced solid tumor with ARID1A mutation.
- •Cohort 1: Platinum-resistant ovarian/fallopian tube/peritoneal clear cell carcinoma with disease progression after ≥1 prior platinum-based regimen. Cohort 2: Endometrial cancer with disease progression after ≥1 prior platinum-based regimen and prior immunotherapy failure or intolerance. Cohort 3: Other advanced solid tumors (including gastric cancer, urothelial carcinoma) with disease progression after ≥1 prior standard systemic therapy.
- •ECOG performance status 0-
- •Life expectancy ≥3 months.
- •At least one measurable lesion per RECIST v1.
- •Adequate organ function: ANC ≥1.5×10⁹/L, PLT ≥100×10⁹/L, Hb ≥100 g/L (no growth factor or transfusion support within 14 days prior to first dose), TBIL ≤1.5×ULN, ALT/AST ≤2.5×ULN (≤5×ULN if liver metastasis), CrCl ≥50 mL/min, LVEF ≥50%, QTcF <450 ms (male) or <470 ms (female).
- •Willing to provide archival or fresh tumor tissue for biomarker analysis.
- •Male and female participants of childbearing potential must agree to use medically approved contraception during the study and for 6 months after the last dose.
排除标准
- •Prior treatment with EZH2 or EZH1/2 inhibitors resulting in disease progression (intolerance permitted).
- •Third-space fluid accumulation not controllable by drainage or other means.
- •Systemic corticosteroid therapy (>10 mg/day prednisone or equivalent) within 14 days prior to first dose, except for inhaled or topical use.
- •Inability to swallow oral medication or conditions significantly affecting drug absorption.
- •Known central nervous system (CNS) involvement.
- •Tumor invasion or encasement of major vessels.
- •Active infection requiring systemic therapy.
- •Active hepatitis B or C requiring treatment, or HIV infection.
- •Active autoimmune disease requiring systemic immunosuppressive therapy.
- •Significant cardiovascular disease (e.g., myocardial infarction within 6 months, NYHA Class III/IV heart failure, uncontrolled arrhythmia).
- •Pregnancy, lactation, or positive pregnancy test.
- •Other primary malignancy within 5 years, except cured non-melanoma skin cancer, carcinoma in situ, or thyroid carcinoma.
- •Prior anti-tumor therapy-related adverse events not recovered to ≤Grade 1 (CTCAE v6.0), except alopecia or peripheral neuropathy Grade ≤
- •Use of strong or moderate CYP3A4 inhibitors/inducers within 14 days prior to first dose.
- •Any other condition that in the investigator's opinion makes the participant unsuitable for the study.
研究组 & 干预措施
TR115 tablet
Experimental
干预措施: TR115 (Drug)
结局指标
主要结局
Objective Response Rate (ORR)
时间窗: Up to approximately 24 months
次要结局
- Overall Survival (OS)(up to approximately 36 months)
- Disease Control Rate (DCR)(up to approximately 24 months.)
- Incidence and severity of adverse events (AEs)(from first dose through 30 days after last dose)
- serious adverse events (SAEs)(first dose through 30 days after last dose)
- laboratory abnormalities graded by CTCAE v6.0,(first dose through 30 days after last dose)
- Duration of Response (DoR)(up to approximately 36 months)
- Progression-Free Survival (PFS)(up to approximately 36 months)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
2 期
A Study Evaluating the Efficacy and Safety of ABP1011T Tablets in Patients With Advanced Solid TumorsNCT07321574Shanghai AB PharmaTech Ltd.110
尚未招募
3 期
TR115 VS Investigator's Choice in Relapsed/Refractory Peripheral T/NK Cell LymphomaPTCLNCT07639879Tarapeutics Science Inc.180
招募中
1 期
A Study of ONO-4538HSC in Pediatric Patients With Malignant Solid Tumors and in Patients With Epithelioid Sarcoma.Pediatric Malignant Solid Tumor and Epithelioid SarcomaNCT07734116Ono Pharmaceutical Co., Ltd.50
招募中
2 期
Fostrox Plus Lenvatinib vs Lenvatinib in Advanced Hepatocellular Carcinoma After First-line ImmunotherapyNCT07493668CHA University80
已完成
4 期
A study to evaluate Efficacy and Safety of the 3-Drug Combination (Chlorzoxazone, Paracetamol and Aceclofenac) in comparison with 2-Drug Combination (Paracetamol and Aceclofenac) for treating adult patients with Acute Musculoskeletal Pain Associated with Spasm.CTRI/2025/04/085094Unison Pharmaceuticals Pvt. Ltd.200